Open access
Open access
Powered by Google Translator Translator

M-A of randomized trials | Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer.

20 Sep, 2022 | 13:23h | UTC

Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials – ESMO Open

Related:

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial – JAMA Surgery

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer – New England Journal of Medicine

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.